Brought to you by 
CNS drug developer Newron grosses CHF118mm in IPO on SWX
18 Dec 2006
Executive Summary
Italian firm Newron Pharmaceuticals SPA (CNS diseases) has raised CHF118mm ($99mm) through its initial public offering on the SWX Swiss Exchange. It sold 2.15mm shares for CHF55 each, landing in the upper end of its planned CHF45-60 price range.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com